Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. filed this Current Report on Form 8-K on September 8, 2022, under Item 1.01 and Item 9.01. The filing reports entry into an at-the-market equity sales agreement; it does not provide quarterly or annual operating results.
Material Financing Agreement
- Celularity may offer and sell, from time to time, up to $150.0 million of Class A common stock.
- BTIG, LLC, Oppenheimer & Co. Inc., and B. Riley Securities, Inc. will act as sales agents and/or principals.
- Shares may be sold through Nasdaq, block transactions, or other legally permitted at-the-market methods.
- Celularity is not obligated to sell any shares. Sales will depend on market conditions, capital-raising needs, and company instructions.
- The sales agents will receive a commission equal to 3.0% of gross sales proceeds from shares sold through them, in addition to reimbursement of specified expenses.
- The offering is registered under Celularity’s effective Form S-3 registration statement filed August 11, 2022, and declared effective August 18, 2022.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt balances, cash balances, liquidity measures, or other operating financial metrics. The potential offering provides an additional financing source but could result in dilution to existing holders if shares are issued.
Changes, Outlook, Risks, and Unusual Items
- This filing establishes a new potential equity financing facility with aggregate capacity of up to $150.0 million.
- No guidance, earnings outlook, or management forecast is provided.
- The timing, volume, and price of any sales are uncertain and subject to market conditions and Celularity’s financing requirements.
- Issuance of shares may dilute existing shareholders and could pressure the stock price depending on the size and timing of sales.
- The agreement includes customary representations, conditions, indemnification, and contribution provisions. The complete terms are contained in Exhibit 1.1.
Key Facts for Investors to Verify
- Whether Celularity has sold any shares under the facility and the aggregate proceeds received.
- The number of shares issued, net proceeds after commissions and expenses, and resulting shareholder dilution.
- Celularity’s cash runway, capital requirements, debt obligations, and subsequent financing activity in later filings.
- The company’s latest operating results and risk-factor disclosures, which are not included in this 8-K.
- The full At-the-Market Sales Agreement filed as Exhibit 1.1 and related prospectus supplements.